A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events

Journal of Cell Science

Volumn 124, Issue 9, 2011, Pages 1453-1464

  Valapala, Mallika ^a   Thamake, Sanjay I ^a   Vishwanatha, Jamboor K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Angiogenesis; Annexin A2; Plasmin; Retinal neovascularization; Tissue plasminogen activator

Indexed keywords

HEXAPEPTIDE; LCKLSL; LIPOCORTIN 2; PLASMIN; PROTEIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NERVE SPROUTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETINA CELL;

ANIMALS; ANNEXIN A2; CELL HYPOXIA; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MICE; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; PROTEIN BINDING; RETINA; TISSUE PLASMINOGEN ACTIVATOR;

MURINAE;

EID: 79955548255     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.079236     Document Type: Article

References (55)

1. Adler, J. and Parmryd, I. (2010). Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient. Cytometry A 77, 733-742.
2. Almér, L. O., Pandolfi, M. and Osterlin, S. (1975). The fibrinolytic system in patients with diabetes mellitus with special reference to diabetic retinopathy. Ophthalmologica 170, 353-361.
3. Arjamaa, O. and Nikinmaa, M. (2006). Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors. Exp. Eye Res. 83, 473-483.
4. Auerbach, R., Lewis, R., Shinners, B., Kubai, L. and Akhtar, N. (2003). Angiogenesis assays: a critical overview. Clin. Chem. 49, 32-40.
5. Berndt, A., Johannesson, J., Haas, M., Arkona, C., Katenkamp, D., Wiederanders, B., Hyckel, P. and Kosmehl, H. (2000). Simultaneous enzyme overlay membrane (EOM)-based in situ zymography and immunofluorescence technique reveals cathepsin B-like activity in a subset of tumour vessels. Histochem. Cell Biol. 114, 63-68.
6. Castellino, F. J. and Ploplis, V. A. (2005). Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93, 647-654.
7. Cesarman, G. M., Guevara, C. A. and Hajjar, K. A. (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem. 269, 21198-21203.
8. Chen, L., Endler, A. and Shibasaki, F. (2009). Hypoxia and angiogenesis: regulation of hypoxia-inducible factors via novel binding factors. Exp. Mol. Med. 41, 849-857.
9. Cheresh, D. A. and Stupack, D. G. (2008). Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 27, 6285-6298.
10. Connor, K. M., Krah, N. M., Dennison, R. J., Aderman, C. M., Chen, J., Guerin, K. I., Sapieha, P., Stahl, A., Willett, K. L. and Smith, L. E. (2009). Quantification of oxygen-induced retinopathy in the mouse: A model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 4, 1565-1573.
11. Day, F. A. and Neufeld, D. A. (1997). Use of enzyme overlay membranes to survey proteinase activity in frozen sections: cathepsin-like and plasmin-like activity in regenerating newt limbs. J. Histochem. Cytochem. 45, 779-783.
12. Donovan, D., Brown, N. J., Bishop, E. T. and Lewis, C. E. (2001). Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4, 113-121.
13. Folkman, J. (2003). Fundamental concepts of the angiogenic process. Curr. Mol. Med. 3, 643-651.
14. Fukao, H., Ueshima, S., Okada, K. and Matsuo, O. (1997). The role of the pericellular fibrinolytic system in angiogenesis. Jpn. J. Physiol. 47, 161-171.
15. Genetos, D. C., Wong, A., Watari, S. and Yellowley, C. E. (2010). Hypoxia increases annexin A2 expression in osteoblastic cells via VEGF and ERK. Bone 47, 1013-1019.
16. Grant, M. B. and Guay, C. (1991). Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest. Ophthalmol. Vis. Sci. 32, 53-64.
17. Griffioen, A. W. and Molema, G. (2000). Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52, 237-268.
18. Hajjar, K. A. and Acharya, S. S. (2000). Annexin II and regulation of cell surface fibrinolysis. Ann. N. Y. Acad. Sci. 902, 265-271.
19. Hajjar, K. A. and Deora, A. (2000). New concepts in fibrinolysis and angiogenesis. Curr. Atheroscler. Rep. 2, 417-421.
20. Hajjar, K. A. and Menell, J. S. (1997). Annexin II: A novel mediator of cell surface plasmin generation. Ann. N. Y. Acad. Sci. 15, 337-349.
21. Hajjar, K. A., Jacovina, A. T. and Chacko, J. (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. identity with annexin II. J. Biol. Chem. 269, 21191-21197.
22. Hajjar, K. A., Mauri, L., Jacovina, A. T., Zhong, F., Mirza, U. A., Padovan, J. C. and Chait, B. T. (1998). Tissue plasminogen activator binding to the annexin II tail domain. direct modulation by homocysteine. J. Biol. Chem. 273, 9987-9993.
23. Hattenbach, L. O., Allers, A., Gümbel, H. O., Scharrer, I. and Koch, F. H. (1999). Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. Retina 19, 383-389.
24. Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J. and Ferrara, N. (1992). Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem. 267, 26031-26037.
25. Jacovina, A. T., Zhong, F., Khazanova, E., Lev, E., Deora, A. B. and Hajjar, K. A. (2001). Neuritogenesis and the nerve growth factor-induced differentiation of PC-12 cells requires annexin II-mediated plasmin generation. J. Biol. Chem. 276, 49350-49358.
26. Kim, J. and Hajjar, K. A. (2002). Annexin II: A plasminogen-plasminogen activator coreceptor. Front. Biosci. 1, 341-348.
27. Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P. and Kerbel, R. S. (2000). Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24.
28. Kumar, R., Yoneda, J., Bucana, C. D. and Fidler, I. J. (1998). Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int. J. Oncol. 12, 749-757.
29. Lijnen, H. R. (2001). Elements of the fibrinolytic system. Ann. N. Y. Acad. Sci. 936, 226-236.
30. Ling, Q., Jacovina, A. T., Deora, A., Febbraio, M., Simantov, R., Silverstein, R. L., Hempstead, B., Mark, W. H. and Hajjar, K. A. (2004). Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest. 113, 38-48.
31. Liu, J., Rothermund, C. A., Ayala-Sanmartin, J. and Vishwanatha, J. K. (2003). Nuclear annexin II negatively regulates growth of LNCaP cells and substitution of ser 11 and 25 to glu prevents nucleo-cytoplasmic shuttling of annexin II. BMC Biochem. 4, 10.
32. Mai, J., Finley, R.L. Jr, Waisman, D.M. and Sloane, B.F. (2000). Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 275, 12806-12812.
33. Merchan, J. R., Kovacs, K., Railsback, J. W., Kurtoglu, M., Jing, Y., Pina, Y., Gao, N., Murray, T. G., Lehrman, M. A. and Lampidis, T. J. (2010). Antiangiogenic activity of 2-deoxy-D-glucose. PLoS ONE 5, e13699.
34. Milkiewicz, M., Panovic, E., Doyle, J. L. and Haas, T. L. (2006). Regulators of angiogenesis and strategies for their therapeutic manipulation. Int. J. Biochem. Cell Biol. 38, 333-357.
35. Nguyen, T. T. and Wong, T. Y. (2009). Retinal vascular changes and diabetic retinopathy. Curr. Diab. Rep. 9, 277-283.
36. Parfyonova, Y. V., Plekhanova, O. S. and Tkachuk, V. A. (2002). Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc.) 67, 119-134.
37. Pepper, M. S. (2001). Extracellular proteolysis and angiogenesis. Thromb. Haemost. 86, 346-355.
38. Pepper, M. S., Ferrara, N., Orci, L. and Montesano, R. (1991). Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181, 902-906.
39. Pepper, M. S., Montesano, R., Mandriota, S. J., Orci, L. and Vassalli, J. D. (1996). Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 49, 138-162.
40. Peterson, E. A., Sutherland, M. R., Nesheim, M. E. and Pryzdial, E. L. (2003). Thrombin induces endothelial cell-surface exposure of the plasminogen receptor annexin 2. J. Cell. Sci. 116, 2399-2408.
41. Ponce, M. L. (2009). Tube formation: an in vitro Matrigel angiogenesis assay. Methods Mol. Biol. 467, 183-188.
42. Roda, O., Valero, M. L., Peiró, S., Andreu, D., Real, F. X. and Navarro, P. (2003). New insights into the tPA-annexin A2 interaction. is annexin A2 CYS8 the sole requirement for this association? J. Biol. Chem. 278, 5702-5709.
43. Roy, R., Zhang, B. and Moses, M. A. (2006). Making the cut: protease-mediated regulation of angiogenesis. Exp. Cell Res. 312, 608-622.
44. Scott, A. and Fruttiger, M. (2010). Oxygen-induced retinopathy: a model for vascular pathology in the retina. Eye (Lond.) 24, 416-421.
45. Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
46. Simpson, A. J., Booth, N. A., Moore, N. R., Lewis, S. J. and Gray, R. S. (1999). Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. Acta Diabetol. 36, 155-158.
47. Sone, H., Kawakami, Y., Segawa, T., Okuda, Y., Sekine, Y., Honmura, S., Segawa, T., Suzuki, H., Yamashita, K. and Yamada, N. (1999). Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy. Life Sci. 65, 2573-2580.
48. Sulochana, K. N. and Ge, R. (2007). Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr. Pharm. Des. 13, 2074-2086.
49. Valdes, T. I., Kreutzer, D. and Moussy, F. (2002). The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials. J. Biomed. Mater. Res. 62, 273-282.
50. van Hinsbergh, V. W., Engelse, M. A. and Quax, P. H. (2006). Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler. Thromb. Vasc. Biol. 26, 716-728.
51. Vu, M. T., Smith, C. F., Burger, P. C. and Klintworth, G. K. (1985). An evaluation of methods to quantitate the chick chorioallantoic membrane assay in angiogenesis. Lab. Invest. 53, 499-508.
52. Werb, Z., Vu, T. H., Rinkenberger, J. L. and Coussens, L. M. (1999). Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS 107, 11-18.
53. Zhao, S., Huang, L., Wu, J., Zhang, Y., Pan, D. and Liu, X. (2009). Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. Mol. Vis. 15, 1231-1242.
54. Zhao, S. H., Pan, D. Y., Zhang, Y., Wu, J. H., Liu, X. and Xu, Y. (2010). Annexin A2 promotes choroidal neovascularization by increasing vascular endothelial growth factor expression in a rat model of argon laser coagulation-induced choroidal neovascularization. Chin. Med. J. (Engl.) 123, 713-721.
55. Zinchuk, V. and Grossenbacher-Zinchuk, O. (2009). Recent advances in quantitative colocalization analysis: focus on neuroscience. Prog. Histochem. Cytochem. 44, 125-172.